All Stories

  1. Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma

    Article • International Journal of Molecular Sciences, August 2023, MDPI AG

    Nicholas Geraghty

  2. The Emerging Roles of Extracellular Chaperones in Complement Regulation

    Article • Cells, December 2022, MDPI AG

    Nicholas Geraghty

  3. Humanized Mouse Model to Study the P2X7 Receptor in Graft-Versus-Host Disease

    Article • January 2022, Springer Science + Business Media

    Nicholas Geraghty

  4. Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation

    Article • Science Advances, December 2021, American Association for the Advancement of Science

    Nicholas Geraghty, Professor Michele Vendruscolo

  5. Expanding the family of extracellular chaperones: Identification of human plasma proteins with chaperone activity

    Article • Protein Science, October 2021, Wiley

    Nicholas Geraghty

  6. Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease

    Article • International Journal of Molecular Sciences, August 2021, MDPI AG

    Nicholas Geraghty

  7. P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model

    Article • Clinical Science, February 2021, Portland Press Ltd.

    Nicholas Geraghty

  8. Streptococcus pyogenes M1T1 Variants Induce an Inflammatory Neutrophil Phenotype Including Activation of Inflammatory Caspases

    Article • Frontiers in Cellular and Infection Microbiology, January 2021, Frontiers

    Nicholas Geraghty

  9. Amyotrophic Lateral Sclerosis: Proteins, Proteostasis, Prions, and Promises

    Article • Frontiers in Cellular Neuroscience, November 2020, Frontiers

    Nicholas Geraghty

  10. Comparison of peripheral blood mononuclear cell isolation techniques and the impact of cryopreservation on human lymphocytes expressing CD39 and CD73

    Article • Purinergic Signalling, August 2020, Springer Science + Business Media

    Nicholas Geraghty

  11. Telomere length varies substantially between blood cell types in a reptile

    Article • Royal Society Open Science, June 2020, Royal Society Publishing

    Nicholas Geraghty

  12. Streptococcus pyogenesM1T1 variants activate caspase-1 and induce an inflammatory neutrophil phenotype

    Article • March 2020, Cold Spring Harbor Laboratory Press

    Nicholas Geraghty

  13. The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice

    Article • Purinergic Signalling, March 2020, Springer Science + Business Media

    Nicholas Geraghty

  14. Increased P2X7 expression in the gastrointestinal tract and skin in a humanised mouse model of graft-versus-host disease

    Article • Clinical Science, January 2020, Portland Press Ltd.

    Nicholas Geraghty

  15. The A2A receptor agonist CGS 21680 has beneficial and adverse effects on disease development in a humanised mouse model of graft-versus-host disease

    Article • International Immunopharmacology, July 2019, Elsevier

    Nicholas Geraghty

  16. Increased splenic human CD4+:CD8+ T cell ratios, serum human interferon-γ and intestinal human interleukin-17 are associated with clinical graft-versus-host disease in humanized mice

    Article • Transplant Immunology, June 2019, Elsevier

    Nicholas Geraghty

  17. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft‐versus‐host disease

    Article • Immunology and Cell Biology, April 2019, Wiley

    Nicholas Geraghty

  18. Altered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised mice

    Article • Purinergic Signalling, April 2019, Springer Science + Business Media

    Nicholas Geraghty

  19. Long-term treatment with the P2X7 receptor antagonist Brilliant Blue G reduces liver inflammation in a humanized mouse model of graft-versus-host disease

    Article • Cellular Immunology, February 2019, Elsevier

    Nicholas Geraghty

  20. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus -host disease

    Article • Clinical & Experimental Immunology, July 2017, Wiley

    Nicholas Geraghty

  21. The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice

    Article • Purinergic Signalling, June 2017, Springer Science + Business Media

    Nicholas Geraghty

  22. P2X7 receptor in skin biology and diseases

    Article • World Journal of Dermatology, January 2016, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Nicholas Geraghty

  23. Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells

    Article • Immunology and Cell Biology, August 2014, Wiley

    Nicholas Geraghty